Compare HURC & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURC | WHWK |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.3M | 179.8M |
| IPO Year | 1995 | N/A |
| Metric | HURC | WHWK |
|---|---|---|
| Price | $16.99 | $4.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 16.9K | ★ 188.1K |
| Earning Date | 03-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,554,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.19 | $1.39 |
| 52 Week High | $21.46 | $4.40 |
| Indicator | HURC | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 68.09 |
| Support Level | $16.29 | $1.84 |
| Resistance Level | $17.00 | $4.40 |
| Average True Range (ATR) | 0.60 | 0.29 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 80.62 | 94.58 |
Hurco Companies Inc is an international industrial technology company that designs, manufactures, and sells computerized (CNC) machine tools for the metal cutting industry through a international sales and distribution network. Its proprietary control systems and software are sold as integral components of its machine tools. The Company also provides machine tool components, automation solutions, software options, upgrades, accessories, replacement parts, and related support services. It operates in the Americas, Europe, and Asia Pacific, with the Americas contributing the majority of revenue. Its core products include vertical and horizontal machining centers (mills), turning centers (lathes), and toolroom machines.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.